Enzymatics has launched version 3.0 of its Archer Analysis Pipeline. It's the latest incarnation of the company's next-generation sequence analysis platform for detecting and characterizing cancer-causing gene fusions and mutations from clinical samples. The solution lets users call known or novel genomic alterations. It includes robust quality control systems, clear, detailed analytics, and interactive visualizations using JBrowse, among other features.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.